Browse the corpus

Bisoprolol is a medication used to manage and treat hypertension and congestive heart failure. The drug belongs to the selective beta-blocker class of drugs and acts explicitly as a cardioselective beta1-blocker (B1-blocker). Bisoprolol mainly focuses on beta1 receptors in the heart to address several heart conditions, such as congestive heart failure. The drug does not affect the undesirable B2 receptors, which could affect different bodily systems. Selective B1-blockers, including bisoprolol, have adverse inotropic and chronotropic effects, decreasing heart contractions and heart rate. Consequently, bisoprolol reduces the oxygen consumption of myocardial cells, relieving the heart's workload. B1 receptors are also present in the juxtaglomerular cells of the kidneys. By blocking these receptors, bisoprolol reduces the release of renin, thereby blocking the activation of the renin-angiotensin system. This dual action on the heart and kidneys makes bisoprolol effective in managing hypertension and related conditions. This activity discusses the indications, mechanism of action, and contraindications for bisoprolol in managing hypertension and other relevant disorders. This resource also covers the adverse event profile and other key factors, including the off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, and relevant interactions of bisoprolol, pertinent to interprofessional healthcare teams when treating patients with hypertension and related conditions. Objectives: Identify appropriate indications for bisoprolol therapy, including hypertension, heart failure, and certain arrhythmias. Screen patients for contraindications and risk factors before initiating bisoprolol treatment, such as bradycardia, heart block, asthma, or severe peripheral vascular disease. Assess patients' response to bisoprolol therapy, monitoring blood pressure, heart rate, and signs of adverse effects. Apply evidence-based guidelines and clinical recommendations to optimize bisoprolol therapy for individual patients. Access free multiple choice questions on this topic.

The toxicity of cardio-selective beta-blockers occurs after ingesting a high dose of the drug, either intentionally or unintentionally. Toxicity can be asymptomatic in some patients, but treatment is always required. Patients in such cases usually present with bradycardia and hypotension. In addition, selective beta-blockers in high doses lose their selectivity, causing patients to demonstrate signs of respiratory distress, congestive heart failure, and neurological manifestations, such as confusion and mental retardation, hypoglycemia, and hyperkalemia. The beta-blocker overdose treatment protocol includes several medicines based on the signs and symptoms of clinical toxicity.[46][47] Sympathomimetic agents (IV atropine or isoproterenol) are used in patients who experience bradycardia. To antagonize beta-blocker-induced hypotension, the clinician should administer intravenous glucagon and fluid. Epinephrine may be ineffective in anaphylaxis induced by beta blockers. Glucagon stimulates heart contraction by glucagon receptors, which are not blocked by beta-blockers.[48] To reverse the bronchospasm induced by beta-blockers, isoproterenol, and aminophylline can be used. Depending on the patient's hemodynamic stability, hypoglycemia can be addressed by administering glucose orally or IV. The patient needs to be monitored carefully in case of a heart block and should be treated with isoproterenol infusion or transvenous cardiac pacemaker insertion.[49] Congestion and impaired perfusion status should be accurately determined in acute decompensated heart failure due to severe overdose. Digitalis, diuretics, inotropic agents, and vasopressors should be used according to hemodynamic status.[50]

Clinicians prescribe bisoprolol for hypertension, Heart failure with reduced ejection fraction, and coronary artery disease. Bisoprolol can mask the symptoms of hypoglycemia in diabetes; drug interactions can lead to bradycardia and AV block. In addition, abrupt withdrawal of bisoprolol can be life-threatening as it can cause life-threatening tachycardia, rebound hypertension, and in some cases, angina. With careful monitoring of the patient's heart rate, blood pressure, temperature, and renal function, the clinician must know the possible adverse drug reactions and their appropriate management. The cardiologist's role is crucial in managing coronary artery disease. Arrhythmias refractory to bisoprolol therapy may require EP consultation. Patient care delivered by heart failure specialists is associated with lower mortality rates.[51] Pharmacists must be aware of the required doses of the drug for each patient and perform medication reconciliation. Nurses can counsel the patients regarding administration and, along with the pharmacist, counsel the patient on potential adverse effects. Pharmacists and nurses must report any issues with the therapy regimen to the prescribing clinician for corrective action. Bisoprolol toxicity from accidental overdose is also possible in a patient with hypertension, so it is essential to know how to antagonize the drug's effect using high-dose glucagon. A study demonstrated that inpatient services delivered by medical toxicologists are associated with reduced length of stay and mortality in poisoning and overdose.[52] A psychiatrist consultation is required if the overdose of bisoprolol is intentional. An interprofessional team approach delivered by physicians, advanced practice practitioners, cardiologists, pulmonologists (for patients with asthma), pharmacists, specialty-trained nursing staff, and toxicologists can achieve optimal patient outcomes related to bisoprolol therapy.